Cargando…
Positron emission tomography (PET) in primary prostate cancer staging and risk assessment
Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, ide...
Autores principales: | Bednarova, Sandra, Lindenberg, Maria L., Vinsensia, Maria, Zuiani, Chiara, Choyke, Peter L., Turkbey, Baris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503952/ https://www.ncbi.nlm.nih.gov/pubmed/28725583 http://dx.doi.org/10.21037/tau.2017.03.53 |
Ejemplares similares
-
Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents
por: Czarniecki, Marcin, et al.
Publicado: (2018) -
Positron Emission Tomography (PET) in Oncology
por: Gallamini, Andrea, et al.
Publicado: (2014) -
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
por: Song, Rachel, et al.
Publicado: (2022) -
Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer
por: Czarniecki, Marcin, et al.
Publicado: (2018) -
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)